Advertisement

Biotech claims for safer stem cells

A California biotech announced at the Stem Cell Summit in New York City on Tuesday that they have successfully reprogrammed human skin, kidney, and retina cells to a stem-cell-like state without using potentially cancer-causing retroviruses. But experts say their claims are impossible to evaluate since the work has not been peer-reviewed. The company researchers did not say these new cells produced teratomas -- the sign that cells are truly pluripotent. The company, PrimeGen Biotech based in

By | February 28, 2008

A California biotech announced at the Stem Cell Summit in New York City on Tuesday that they have successfully reprogrammed human skin, kidney, and retina cells to a stem-cell-like state without using potentially cancer-causing retroviruses. But experts say their claims are impossible to evaluate since the work has not been peer-reviewed. The company researchers did not say these new cells produced teratomas -- the sign that cells are truly pluripotent. The company, PrimeGen Biotech based in Irvine, Ca., said it used carbon-based particles coated with DNA coding for the four transcription factors Oct3/4, SOX2, c-Myc, and Klf4, the New Scientist linkurl:reported.;http://www.newscientist.com/article/dn13384-stem-cell-breakthrough-may-reduce-cancer-risk.html These are the same factors Shinya Yamanaka used with retroviruses to reprogram skin cells into stem cell-like cells linkurl:last November.;http://www.the-scientist.com/blog/display/53873/ In a statement regarding Yamanaka's paper, linkurl:Douglas Melton,;http://www.hhmi.org/research/investigators/melton_bio.html stem cell researcher at Harvard University, said that "retroviruses are a real limitation to stem cell reprogramming" because they can disrupt other genes required for normal cell function. PrimeGen said in an accompanying linkurl:press release;http://www.primegenbiotech.com/news/PR014_(2008-02-26).pdf that they are looking for sponsorship and help in developing their cell lines. But some researchers are skeptical about the company's findings. Until the results go through the peer review process they will be hard to evaluate, linkurl:James Thomson,;http://ink.primate.wisc.edu/~thomson/jamie.html at the University of Wisconsin, Madison, whose group also reported reprogrammed stem cells last November, told linkurl:Forbes.;http://www.forbes.com/business/2008/02/27/biotech-research-cells-biz-cx_mh_0227stem.html One independent researcher who has tested the new cells, linkurl:Denis Clegg;http://www.lifesci.ucsb.edu/mcdb/faculty/clegg/index.html at the University of California, Santa Barbra, told Forbes they behave like embryonic stem cells, but expressed surprise at the company's early announcement.
Advertisement

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement
EMD Millipore
EMD Millipore

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
The Scientist
The Scientist
Advertisement
NeuroScientistNews
NeuroScientistNews
Life Technologies